{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:39Z","timestamp":1790357379716,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03713-9","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:02:34Z","timestamp":1727431354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Ahmed A. Abo","family":"Elnaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Alsaied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M.","family":"Elettreby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abouzid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghda","family":"Shetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan A.","family":"Al-Ajlouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"3713_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1542\/pir.2021-005259","volume":"44","author":"VS Keskinyan","year":"2023","unstructured":"Keskinyan VS, Lattanza B, Reid-Adam J. Glomerulonephritis Pediatr Rev. 2023;44:498\u2013512.","journal-title":"Glomerulonephritis Pediatr Rev"},{"key":"3713_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.kint.2016.04.026","volume":"90","author":"JB Wetmore","year":"2016","unstructured":"Wetmore JB, Guo H, Liu J, Collins AJ, Gilbertson DT. The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. Kidney Int. 2016;90:853\u201360.","journal-title":"Kidney Int"},{"key":"3713_CR3","first-page":"247","volume":"60","author":"G \u0218tefan","year":"2024","unstructured":"\u0218tefan G, Zugravu A, Stancu S. Mortality in IgA nephropathy: a long-term Follow-Up of an eastern European cohort. Med (Mex). 2024;60:247.","journal-title":"Med (Mex)"},{"key":"3713_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/j.ackd.2011.03.005","volume":"18","author":"J Kiffel","year":"2011","unstructured":"Kiffel J, Rahimzada Y, Trachtman H. Focal segmental glomerulosclerosis and chronic kidney Disease in Pediatric patients. Adv Chronic Kidney Dis. 2011;18:332\u20138.","journal-title":"Adv Chronic Kidney Dis"},{"key":"3713_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Semin Nephrol. 2018;38:435\u201342.","journal-title":"Semin Nephrol"},{"key":"3713_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut P, Avila-Casado C, Reich HN. IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021;78:429\u201341.","journal-title":"Am J Kidney Dis"},{"key":"3713_CR7","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/ndt\/gfad146","volume":"38","author":"PJ Gleeson","year":"2023","unstructured":"Gleeson PJ, O\u2019Shaughnessy MM, Barratt J. IgA nephropathy in adults\u2014treatment standard. Nephrol Dial Transpl. 2023;38:2464\u201373.","journal-title":"Nephrol Dial Transpl"},{"key":"3713_CR8","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.3390\/jcm10194501","volume":"10","author":"B Knoppova","year":"2021","unstructured":"Knoppova B, Reily C, King RG, Julian BA, Novak J, Green TJ. Pathogenesis of IgA Nephropathy: current understanding and implications for development of Disease-Specific treatment. J Clin Med. 2021;10:4501.","journal-title":"J Clin Med"},{"key":"3713_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","volume":"33","author":"SC Yeo","year":"2018","unstructured":"Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy. Pediatr Nephrol. 2018;33:763\u201377.","journal-title":"Pediatr Nephrol"},{"key":"3713_CR10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/diagnostics13020303","volume":"13","author":"Y Du","year":"2023","unstructured":"Du Y, Cheng T, Liu C, Zhu T, Guo C, Li S, et al. IgA nephropathy: current understanding and perspectives on Pathogenesis and targeted treatment. Diagnostics. 2023;13:303.","journal-title":"Diagnostics"},{"key":"3713_CR11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12882-022-03002-3","volume":"23","author":"K Sausukpaiboon","year":"2022","unstructured":"Sausukpaiboon K, Panombualert S, Wisanuyotin S, Puapairoj A, Suparattanagool P, Techasatian L, et al. Clinical manifestations and pathological correlation of immunoglobulin A nephropathy in children. BMC Nephrol. 2022;23:366.","journal-title":"BMC Nephrol"},{"key":"3713_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41581-021-00427-1","volume":"17","author":"AS De Vriese","year":"2021","unstructured":"De Vriese AS, Wetzels JF, Glassock RJ, Sethi S, Fervenza FC. Therapeutic trials in adult FSGS: lessons learned and the road forward. Nat Rev Nephrol. 2021;17:619\u201330.","journal-title":"Nat Rev Nephrol"},{"key":"3713_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3765608","volume":"2016","author":"E K\u00f6nigshausen","year":"2016","unstructured":"K\u00f6nigshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates. BioMed Res Int. 2016;2016:1\u20139.","journal-title":"BioMed Res Int"},{"key":"3713_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/antib12020040","volume":"12","author":"D Petrou","year":"2023","unstructured":"Petrou D, Kalogeropoulos P, Liapis G, Lionaki S. IgA nephropathy: current treatment and New insights. Antibodies. 2023;12:40.","journal-title":"Antibodies"},{"key":"3713_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ekir.2022.10.004","volume":"8","author":"M De Cos","year":"2023","unstructured":"De Cos M, Meliambro K, Campbell KN. Novel Treatment paradigms: focal segmental glomerulosclerosis. Kidney Int Rep. 2023;8:30\u20135.","journal-title":"Kidney Int Rep"},{"key":"3713_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.matbio.2018.02.017","volume":"68\u201369","author":"M Allinovi","year":"2018","unstructured":"Allinovi M, De Chiara L, Angelotti ML, Becherucci F, Romagnani P. Anti-fibrotic treatments: a review of clinical evidence. Matrix Biol. 2018;68\u201369:333\u201354.","journal-title":"Matrix Biol"},{"key":"3713_CR17","unstructured":"Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI\u2122 (sparsentan.), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy."},{"key":"3713_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/psp4.12996","volume":"12","author":"R Wada","year":"2023","unstructured":"Wada R, Kleijn HJ, Zhang L, Chen S. Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis. CPT Pharmacomet Syst Pharmacol. 2023;12:1080\u201392.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"3713_CR19","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1681\/ASN.2013020195","volume":"25","author":"O Lenoir","year":"2014","unstructured":"Lenoir O, Milon M, Virsolvy A, H\u00e9nique C, Schmitt A, Mass\u00e9 J-M, et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol JASN. 2014;25:1050\u201362.","journal-title":"J Am Soc Nephrol JASN"},{"key":"3713_CR20","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1021\/jm058225d","volume":"48","author":"R Morphy","year":"2005","unstructured":"Morphy R, Rankovic Z. Designed multiple ligands. An Emerging Drug Discovery paradigm. J Med Chem. 2005;48:6523\u201343.","journal-title":"J Med Chem"},{"key":"3713_CR21","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. 1st ed. Wiley; 2019 [cited 2024 Mar 7]. https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"3713_CR22","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71.","DOI":"10.1136\/bmj.n71"},{"key":"3713_CR23","unstructured":"EndNote. | The Best Citation & Reference Management Tool [Internet]. EndNote. [cited 2023 Sep 19]. https:\/\/endnote.com\/"},{"key":"3713_CR24","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"3713_CR25","unstructured":"RevMan [Internet]. [cited 2023 Sep 14]. https:\/\/training.cochrane.org\/online-learning\/core-software\/revman"},{"key":"3713_CR26","unstructured":"Joanne E, McKenzie SE, Brennan RE, Ryan HJ, Thomson RV, Johnston. Chapter 9: Summarizing study characteristics and preparing for synthesis. Cochrane Handb Syst Rev Interv [Internet]. Cochrane; 2023 [cited 2023 Dec 4]. https:\/\/training.cochrane.org\/handbook\/current\/chapter-09"},{"key":"3713_CR27","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1681\/ASN.2018010091","volume":"29","author":"H Trachtman","year":"2018","unstructured":"Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, et al. DUET: a phase 2 study evaluating the efficacy and safety of Sparsentan in patients with FSGS. J Am Soc Nephrol. 2018;29:2745\u201354.","journal-title":"J Am Soc Nephrol"},{"key":"3713_CR28","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","volume":"389","author":"MN Rheault","year":"2023","unstructured":"Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae D-W, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023;389:2436\u201345.","journal-title":"N Engl J Med"},{"key":"3713_CR29","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401:1584\u201394.","journal-title":"Lancet"},{"key":"3713_CR30","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402:2077\u201390.","journal-title":"Lancet"},{"key":"3713_CR31","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN, Troyanov SAA, Scholey JW, Cattran DC. Remission of Proteinuria improves prognosis in IgA Nephropathy. J Am Soc Nephrol. 2007;18:3177\u201383.","journal-title":"J Am Soc Nephrol"},{"key":"3713_CR32","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2215\/CJN.04780517","volume":"13","author":"JP Troost","year":"2018","unstructured":"Troost JP, Trachtman H, Nachman PH, Kretzler M, Spino C, Komers R, et al. An outcomes-based definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2018;13:414\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3713_CR33","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Inker A, Floege L, Perkovic J, Boyer-Suavet V. Proteinuria Reduction as a surrogate end point in trials of IgA Nephropathy. Clin J Am Soc Nephrol. 2019;14:469\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3713_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","volume":"77","author":"JP Troost","year":"2021","unstructured":"Troost JP, Trachtman H, Spino C, Kaskel FJ, Friedman A, Moxey-Mims MM, et al. Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis. Am J Kidney Dis. 2021;77:216\u201325.","journal-title":"Am J Kidney Dis"},{"key":"3713_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.athoracsur.2008.05.007","volume":"86","author":"R Jin","year":"2008","unstructured":"Jin R, Grunkemeier GL, Brown JR, Furnary AP. Estimated glomerular filtration rate and renal function. Ann Thorac Surg. 2008;86:1\u20133.","journal-title":"Ann Thorac Surg"},{"key":"3713_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in Albuminuria and GFR as End points for clinical trials in early stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020;75:84\u2013104.","journal-title":"Am J Kidney Dis"},{"key":"3713_CR37","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","volume":"29","author":"LA Inker","year":"2023","unstructured":"Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023;29:1867\u201376.","journal-title":"Nat Med"},{"key":"3713_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/IJNRD.S430377","volume":"16","author":"KN Campbell","year":"2023","unstructured":"Campbell KN, Griffin S, Trachtman H, Geletka R, Wong MG. Practical considerations for the Use of Sparsentan in the treatment of patients with IgAN in clinical practice. Int J Nephrol Renov Dis. 2023;16:281\u201391.","journal-title":"Int J Nephrol Renov Dis"},{"key":"3713_CR39","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the management of glomerular diseases. Kidney Int. 2021;100:S1\u2013276.","journal-title":"Kidney Int"},{"key":"3713_CR40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al. Long-term outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023;18:727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3713_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-024-02036-1","volume":"84","author":"L Del Vecchio","year":"2024","unstructured":"Del Vecchio L, Allinovi M, Comolli S, Peiti S, Rimoldi C, Locatelli F. Drugs in Development to treat IgA nephropathy. Drugs. 2024;84:503\u201325.","journal-title":"Drugs"},{"key":"3713_CR42","doi-asserted-by":"crossref","unstructured":"Kwon CS, Daniele P, Forsythe A, Ngai C. A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy. J Health Econ Outcomes Res [Internet]. 2021 [cited 2024 Apr 14];8. https:\/\/jheor.org\/article\/26129-a-systematic-literature-review-of-the-epidemiology-health-related-quality-of-life-impact-and-economic-burden-of-immunoglobulin-a-nephropathy","DOI":"10.36469\/001c.26129"},{"key":"3713_CR43","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.ekir.2017.02.019","volume":"2","author":"R Komers","year":"2017","unstructured":"Komers R, Gipson DS, Nelson P, Adler S, Srivastava T, Derebail VK, et al. Efficacy and safety of Sparsentan compared with Irbesartan in patients with primary focal segmental glomerulosclerosis: Randomized, controlled Trial Design (DUET). Kidney Int Rep. 2017;2:654\u201364.","journal-title":"Kidney Int Rep"},{"key":"3713_CR44","doi-asserted-by":"publisher","first-page":"100457","DOI":"10.1016\/j.xkme.2022.100457","volume":"4","author":"KN Campbell","year":"2022","unstructured":"Campbell KN, Pennese N, Zaffalon A, Magalhaes B, Faiella M, Caster DJ, et al. Efficacy and safety of ACE inhibitor and angiotensin receptor blocker therapies in primary focal segmental glomerulosclerosis treatment: a systematic review and Meta-analysis. Kidney Med. 2022;4:100457.","journal-title":"Kidney Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03713-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:06:37Z","timestamp":1727431597000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03713-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3713"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03713-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"7 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"316"}}